<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502086</url>
  </required_header>
  <id_info>
    <org_study_id>VIUHCV-07</org_study_id>
    <nct_id>NCT00502086</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.</brief_title>
  <official_title>Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the
      mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal
      syndrome, hepatic encephalopathy, gastrointestinal bleeding, sepsis and hepatocellular
      carcinoma) of patients with cirrhosis of the liver secondary to HCV infection in comparison
      with placebo, during 96 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mortality secondary to liver failure at 96 weeks.</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The complication rates during the treatment. The hepatitis-related quality of live during the treatment. Clinical Activity Index during the treatment. The hepatocellular carcinoma incidence during the treatment.</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viusid, three sachets daily during 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo three sachets daily during 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Viusid (nutritional supplement)</intervention_name>
    <description>Viusid three sachets daily during 96 weeks</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Nutritional supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo three sachets daily during 96 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or clinical diagnosis of cirrhosis.

          -  HCV infection confirmed on a positive test for anti-HCV antibody and HCV RNA
             detectable in serum by Polymerase Chain Reaction.

          -  Patients who were non-responders to previous treatment with pegylated interferon and
             ribavirin or naïve patients with decompensated cirrhosis (Child-Pugh score ≥ 7) who
             had contraindicated the antiviral treatment.

          -  Presence of compensated or decompensated (Stage A, B or C according to the Child-Pugh
             Classification).

          -  Absence of clinical and ultrasonographic evidence of liver cancer, with α-fetoprotein
             levels ≤ 200 ng/ml.

        Exclusion Criteria:

          -  Age less than 18 or greater than 70 years.

          -  Presence of uncontrollable clinical or biochemical complications related to severe
             liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal
             bleeding, serum bilirubin level greater than 5 mg/dL, international normalized ratio
             greater than 2.5).

          -  Active alcoholism.

          -  Serum creatinine greater than 2 mg/dL.

          -  Hepatocellular carcinoma.

          -  Refusal to participate in the study.

          -  Concomitant disease with reduced life expectancy.

          -  Severe psychiatric conditions.

          -  Co-infection with hepatitis A or B or HIV.

          -  Drug dependence.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Vilar Gómez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Gastroenterology, Havana, Cuba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Gastroenterology</name>
      <address>
        <city>Plaza de la Revolución</city>
        <state>Havana</state>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <reference>
    <citation>Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int. 2007 Mar;27(2):247-59.</citation>
    <PMID>17311621</PMID>
  </reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Eduardo Vilar Gómez</name_title>
    <organization>National Institute of Gastroenterology</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Cirrhosis of the liver</keyword>
  <keyword>Mortality</keyword>
  <keyword>Complications</keyword>
  <keyword>Health-related quality of live</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Nutritional supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

